Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GERON CORPGERN · Entity 4989 | EVP, Chief Medical Officer | February 16, 2022 | February 18, 2022 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | February 04, 2026 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GERON CORP
Report date February 16, 2022 · Filed February 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.06 · Expires 2032-02-15 | Direct | 750,000 |
Reported balance
After 2022-02-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-16 · Grant · Acquired 750,000 · Balance 750,000 F1: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022, provided the optionee continues to provide services to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022, provided the optionee continues to provide services to the Company.
Syndax Pharmaceuticals Inc
Report date February 04, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,000 |
Reported balance
After 2026-02-04 transaction · row 1
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 24,000 · Balance 49,000 F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 6, 2026 21:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-041194 · ownership.xml · nonDerivative · entry 1 Rizo Aleksandra · CIK 0001766210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:39 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016374 · ownership.xml · nonDerivative · entry 1 Rizo Aleksandra · CIK 0001766210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| May 15, 2024 Filed May 16, 2024 20:04 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 35,000 | $0.00 Strike: $21.94 | $0.00 |
DisclosureSEC source: 0001562180-24-004087 · primarydocument.xml · derivative · entry 1 Rizo Aleksandra · CIK 0001766210 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-05-15 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:05 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001062993-22-005004 · form4.xml · derivative · entry 1 Rizo Aleksandra · CIK 0001766210 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 16, 2022, provided the optionee continues to provide services to the Company. Read SEC document |
| February 02, 2021 Filed Feb 5, 2021 00:41 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0000886744-21-000012 · edgar.xml · derivative · entry 1 Rizo Aleksandra · CIK 0001766210 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2031-02-01 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 2, 2021, provided the optionee continues to provide services to the Company. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:06 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 291,375 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0000886744-20-000015 · edgar.xml · derivative · entry 1 Rizo Aleksandra · CIK 0001766210 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,375 Underlying: Common Stock · 291,375 shares Expires 2030-02-11 F1 · derivative.exercise_date: This option vests in a series of 48 consecutive equal monthly installments commencing February 12, 2020, provided the optionee continues to provide services to the Company. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 23:37 UTC | GERON CORP GERN · Entity 4989 | GrantEmployee Stock Option (right to buy) · Derivative | 750,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000886744-19-000020 · edgar.xml · derivative · entry 1 Rizo Aleksandra · CIK 0001766210 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: This option vests as follows: 93,750 shares on July 30, 2019, the remaining 656,250 shares in a series of 42 equal monthly installments commencing July 30, 2019, provided the optionee continues to provide services to the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.